Related Experiment Video
Updated: May 10, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Competitive but Not Allosteric mTOR Kinase Inhibition Enhances Tumor Cell Radiosensitivity
Thomas J Hayman1, Tamalee Kramp, Jenna Kahn
1University of South Florida Morsani College of Medicine, Tampa, FL ; Radiation Oncology Branch, National Cancer Institute, Bethesda, MD.
Abstract:
The mechanistic target of rapamycin (mTOR) is a critical kinase in the regulation of gene translation and has been suggested as a potential target for radiosensitization. The goal of this study was to compare the radiosensitizing activities of the allosteric mTOR inhibitor rapamycin with that of the competitive mTOR inhibitor PP242. On the basis of immunoblot analyses, whereas rapamycin only partially inhibited mTOR complex 1 (mTORC1) activity and had no effect on mTOR complex 2 (mTORC2), PP242 inhibited the activity of both mTOR-containing complexes. Irradiation alone had no effect on mTORC1 or mTORC2 activity. Clonogenic survival was used to define the effects of the mTOR inhibitors on in vitro radiosensitivity. In the two tumor cell lines evaluated, PP242 treatment 1 hour before irradiation increased radiosensitivity, whereas rapamycin had no effect. Addition of PP242 after irradiation also enhanced the radiosensitivity of both tumor lines. To investigate the mechanism of radiosensitization, the induction and repair of DNA double-strand breaks were evaluated according γH2AX foci. PP242 exposure did not influence the initial level of γH2AX foci after irradiation but did significantly delay the dispersal of radiation-induced γH2AX foci. In contrast to the tumor cell lines, the radiosensitivity of a normal human fibroblast cell line was not influenced by PP242. Finally, PP242 administration to mice bearing U251 xenografts enhanced radiation-induced tumor growth delay. These results indicate that in a preclinical tumor model PP242 enhances tumor cell radiosensitivity both in vitro and in vivo and suggest that this effect involves an inhibition of DNA repair.
Insights
The mechanistic target of rapamycin (mTOR) inhibitor PP242 enhances tumor cell radiosensitivity by delaying DNA repair. Unlike rapamycin, PP242 effectively inhibits both mTOR complexes, improving radiosensitization in vitro and in vivo.
Area of Science:
- Oncology
- Molecular Biology
- Radiotherapy
Background:
- Mechanistic target of rapamycin (mTOR) is crucial for gene translation and a potential radiosensitization target.
- Rapamycin is an allosteric mTOR inhibitor, while PP242 is a competitive inhibitor.
- Understanding differential mTOR inhibition is key for optimizing cancer therapy.
Purpose of the Study:
- To compare the radiosensitizing effects of rapamycin and PP242.
- To investigate the impact of these inhibitors on mTORC1 and mTORC2 activity.
- To elucidate the mechanisms underlying PP242-mediated radiosensitization.
Main Methods:
- Immunoblot analyses to assess mTORC1 and mTORC2 activity.
- Clonogenic survival assays for in vitro radiosensitivity.
- γH2AX foci analysis for DNA double-strand break repair.
- In vivo studies using U251 xenografts in mice.
Main Results:
- PP242 inhibited both mTORC1 and mTORC2, while rapamycin only partially inhibited mTORC1.
- PP242 significantly increased radiosensitivity in tumor cell lines, both before and after irradiation.
- PP242 delayed the repair of radiation-induced DNA double-strand breaks.
- PP242 enhanced radiation-induced tumor growth delay in vivo without affecting normal fibroblasts.
Conclusions:
- PP242 demonstrates superior radiosensitizing activity compared to rapamycin.
- PP242 enhances tumor cell radiosensitivity by inhibiting DNA repair mechanisms.
- PP242 shows promise as a radiosensitizer in preclinical cancer models.
More Related Videos
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Mitogens and the Cell Cycle

